Catalent, Inc.

Catalent, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Catalent, Inc., is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies, and consumer health products. The company specializes in enabling pharma, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

Ticker: CTLT

Humankind Value: $30.8 B

Revenue: $3.0 B

Market Cap: $16.2 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Catalent, Inc. has earned a spot in our top 100. This outcome is largely driven by Healthcare R&D ($21.5 B), Pharmaceuticals ($8.5 B), and Economic Value ($687.2 M). The value associated with Healthcare R&D and Pharmaceuticals includes the impact of an estimated 622,861.3 additional years lived by people worldwide. Catalent produces economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. However, there is room for improvement with respect to Greenhouse Gases (-$222.7 M) and Air Pollution (-$44.9 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings